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Parkinson’s disease most often presents after age 60, and patients in this age group are best man-
aged with levodopa therapy as the primary treatment modality. Unlike young-onset parkinsonism 
(onset ＜age 40), this older age group is much less prone to subsequent development of levodopa re-
sponsive instability (dyskinesias, fluctuations). When these problems do occur in seniors, they usu-
ally can be managed by medication adjustments. The treatment goal is to keep patients active and 
engaged; levodopa dosage should be guided by the patients’ responses and not arbitrarily limited to 
low doses, which may compromise patients’ lives.
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Introduction
This manuscript focuses on the medical treatment of Parkinson’s 
disease (PD) patients over age 60. This senior age-group is much 
less susceptible to the delayed motor complications of levodo-
pa therapy (fluctuations, dyskinesias), compared to young PD 
patients. This age-cohort is highly relevant to practicing clini-
cians since PD develops after age 60 years in more than 80% of 
cases.
1 
PD is a treatable disorder and drug therapy can be very grat-
ifying for both the patient and clinician. PD, however, is progres-
sive; after years, the benefits become less complete and even-
tually additional problems surface that are poorly or incom-
pletely treatable. Thus, clinicians typically are cognizant of both 
the immediate needs of the patient, as well as the progressive 
course of PD that will likely evolve into more disability. Obvi-
ously, there are two therapeutic issues that confront clinicians treat-
ing new PD patients: 1) medical strategies for slowing the course 
of PD; 2) symptomatic treatment. 
Medical Strategies  
for Slowing the Course of PD
Although the published focus is often on the dopaminergic pro-
blems of PD, these often are overshadowed by a myriad of non-
dopaminergic conditions that evolve after years of PD. This in-
cludes cognitive impairment, dysautonomia and levodopa-un-
responsive motor disability.
Cognitive impairment
Mild cognitive impairment is already apparent in 19-29% of ear-
ly PD cases.
2-4 Dementia or mild cognitive impairment was doc-
umented in 85% of the Sydney, Australian PD cohort after 15 
years of follow-up;
5 in Norway, 60% were demented after 12 years.
6 
Age factors into this, and in a USA cohort, 65% were demented 
by age 85 years.
7 The substrate for the dementia is proliferation 
of the Lewy neurodegenerative process.
8-12 In later stage PD, 
dementia often becomes the most disabling problem. Unfortu-
nately, it is poorly responsive to medical treatment, although ace-
tylcholinesterase inhibitors may provide mild benefit.
Dysautonomia
Autonomic problems may precede the motor symptoms of 
PD,
13,14 but are usually mild or minimal during the early years. 
However, advancing PD is often associated with orthostatic hy-
potension causing presyncope/syncope, neurogenic bladder with 
urinary incontinence and severe constipation. These may be dif-




During the early years of PD, the parkinsonian motor symptoms 
typically respond dramatically to aggressive dopamine replen-
ishment. Unfortunately, after a decade or longer, extrapyrami-
dal symptoms surface that fail levodopa and related drugs. This 
is apparent when perusing published data from PD clinical tri-
als; drug treatment of early PD cases results in near-normal mean Initial Treatment for Parkinson’s Disease
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Unified Parkinson’s Disease Rating Scale (UPDRS). However 
clinical drug trials of more advanced PD cases reveals much 
higher UPDRS scores despite maximal medical treatment, con-
sistent with incomplete responses. The substrate for this is, 
again, proliferation of the Lewy neurodegenerative process.
9 
In advanced PD, severe gait instability with falls and levodopa-
unresponsive gait freezing may render patients wheelchair-
bound.
Levodopa motor complications
Instability of the levodopa response, with dyskinesias and mo-
tor fluctuations, also reflects the natural history of PD. Thus, le-
vodopa dyskinesias and fluctuating responses are rare during 
the first years of PD, but with about a 40% risk by five levodo-
pa-treatment years.
19 In contrast, when levodopa was first intro-
duced for general use about 40 years ago, dyskinesias common-
ly developed within the first few months, likely relating to much 
longer durations of PD before treatment.
19 
The substrate for these unstable levodopa responses presum-
ably includes the increasing loss of nigrostriatal dopaminergic 
terminals with PD progression. These presynaptic terminals nor-
mally modulate synaptic concentrations of dopamine; when the 
loss is nearly complete in certain striatal areas, synaptic dopamine 
is no longer controlled, and levels may widely fluctuate. A sec-
ondary consequence of this occurs postsynaptically, where down-
stream responses may amplify these problems.
20 These levodo-
pa motor complications, however, differ from the cognitive, auto-
nomic and levodopa-refractory motor responses discussed 
above in that they are much more treatable. 
Medication adjustments often stabilization fluctuations and 
reduce dyskinesias; when these are unsatisfactory, deep brain 
stimulation is available. Although the medical literature often 
focuses on levodopa dyskinesias and fluctuations, these ulti-
mately contribute much less of declining quality of life (QoL) 
compared to the levodopa-refractory motor symptoms, dementia 
and dysautonomia.
5
Medications for slowing the progression of PD
Over the past 20 years, several drugs proposed to slow PD 
progression were tested in large multi-center trials. Unfortuna-
tely, these trials were ultimately negative or sufficiently con-




25,27 and two inde-
pendent apoptosis inhibitors.
28,29 Thus, the American Academy 
of Neurology (AAN) consensus panel that reviewed these and 
other more limited trials concluded in 2006 that “No treatment 
has been shown to be neuroprotective”.
30 
Following the above pronouncement by the AAN, a multi-
center trial assessing rasagiline for a “disease modifying” effect 
has captured much attention; this is the so-called ADAGIO tri-
al.
31 This study, however, employed a complex design, with cer-
tain counter-intuitive findings (i.e., positive results with only 
the lower of two doses). Careful scrutiny of this data reveals sub-
stantial potential for confounding, and the implications seem 
uninterpretable.
32 
More recently, the US National Institute for Neurological Di-
sorders and Stroke has funded an ongoing program of drug sc-
reening using futility trial design.
33 Although several drugs have 
been evaluated (creatine, minocycline, coenzyme Q10 and the 
neuroimmunophilin, GPI-1485), no drug has advanced beyond 
very preliminary trials.
Conclusion: drugs to slow PD progression
Unfortunately, despite much focus on drugs to slow the course of 
PD, no medications have yet surfaced with proof of true disease-
modifying effects. Thus, the AAN conclusion from 2006 still ho-
lds true: we have no drugs with proof of a neuroprotective effect.
Levodopa and longevity
What should not be overlooked, however, is the rather dramatic 
effect levodopa therapy had on longevity when it was first in-
troduced about four decades ago. Every trial that assessed mor-
tality rates among PD cohorts concluded that the advent of the 
levodopa era was tightly time-locked to a substantial increase 
in longevity.
34-41 Thus, in the current era, mean longevity among 
PD patients is only a few years less than those without PD.
42 Li-
kely, this increase in longevity simply relates to mobilizing PD 
patients, who without symptomatic treatment, would have even-
tually been relegated to a wheelchair-nursing home existence.
Symptomatic Treatment of PD  
Patients Over Age 60: Background
The goals of symptomatic treatment
When considering any medication for any disorder, clinicians 
need appropriate goals to guide treatment. Who needs treatment 
and how aggressively? Since we have no proof that any medi-
cation truly affects the pathogenic PD substrate, the treatment 
target is based on symptoms. There are two sensible goals: 
1) Maintain PD patients in the mainstreams of their lives and 
keep them active; a sedentary lifestyle has it’s own inherent 
health risks. 
2) Optimize QoL.
There is no compelling reason to start any therapy if patients 
remain active, engaged and satisfied. However, declining activi-
ty or QoL due to PD indicates that symptomatic treatment is ap-
propriate. Once patients develop sedentary lifestyles due to PD, 
it is difficult to reverse bad habits and deconditioning. Thus, effi-
cacious medications should be used when PD symptoms become 
compromising. Ahlskog JE
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Which drug is best for symptomatic therapy?
The primary drugs for initial symptomatic treatment are levodo-
pa and the dopamine agonists. Although certain minor PD drugs 
may be used for symptomatic treatment, these should be reser-
ved for patients with minimal problems. This includes such dr-
ugs as selegiline and rasagiline, which have mild symptomatic 
PD benefits. Amantadine also falls into this class, although it 
may have a clear indication later in the course to attenuate dys-
kinesias. Anti-cholinergic drugs no longer can be recommend-
ed for routine use, given their side effects: memory impairment, 
constipation, dry mouth and eyes, blurred vision. 
For the past four decades, the foundation of symptomatic tr-
eatment of PD has been levodopa. This remains the most effi-
cacious medication for PD. Clinicians treating PD must have a 
clear understanding of how and when to use levodopa; all other 
treatment revolves around that. Unfortunately, much of the me-
dical literature provides varied and conflicting guidelines about 
levodopa treatment. When to start, and how aggressive to dose 
has been extensively debated. Conservative use of levodopa has 
been urged because of concerns regarding later-developing mo-
tor complications: fluctuations and dyskinesias. Moreover, cer-
tain early authors raised concerns that levodopa might be tox-
ic. Hence, several issues relating to levodopa therapy deserve 
clarification. 
Is levodopa toxic?
Early investigators questioning the cause of PD focused exclu-
sively on the dopaminergic substantia nigra. The nigra is obvi-
ously a lynchpin in basal ganglia motor control systems and the 
degeneration of this small nucleus translates into dramatic (and 
medically reversible) symptoms. Of course, this overlooks the 
fact that Lewy neurodegeneration extends widely beyond the 
substantia nigra; this accounts for the problems of advancing 
PD with levodopa-refractory motor symptoms, dementia and 
dysautonomia. We now recognize that the PD neurodegenera-
tive process probably starts in non-dopaminergic nuclei, later af-
fecting the nigra and eventually non-dopaminergic neo- and lim-
bic cortex.
43,44 
However, the early focus on the substantia nigra led some 
investigators to propose that the nigral neurotransmitter, dopa-
mine, was inherently cytotoxic, and by extrapolation, levodo-
pa therapy should accelerate PD progression.
45,46 Although 
initial in vitro studies reported dopamine toxicity, this was 
later shown to be an artifact of the cell culture medium.
47 
Both animal and human studies have failed to identify evidence 
of levodopa toxicity
48,49 and this includes the large multicenter 
clinical trial specifically designed to asses such toxicity.
50 No-
table, also is the fact that some dopaminergic nuclei are largely 
spared in PD.
51 Thus, concerns about levodopa toxicity have 
largely been put to rest.
Should the dose of levodopa be restricted?
Some authors advise conservative dosing with levodopa; per-
haps this might translate into better responses years later. In clini-
cal practice, however, it is apparent that many PD symptoms 
tend to respond in an all-or-none manner, as if there is a dose 
threshold.
52 Thus, restricting the dose may translate into inade-
quate benefit, contrary to our above goals of maximizing activ-
ity and QoL. Only a single clinical trial has assessed this, com-
paring “low dose” carbidopa/levodopa to optimal dosing (“high 
dose”).
53 After six years, parkinsonism in the low dose group was 
poorly controlled and moreover, there were not dramatic differ-
ences in the frequencies of levodopa fluctuations or dyskinesias. 
The authors concluded that dose restriction was not beneficial, 
early or later.
In clinical practice, optimal individual levodopa doses vary 
among patients. However, it seems rational to identify the dose 
that works the best in any given patient and utilize that. Unlike 
narcotics, where the doses must be continuously increased to 
maintain an effect, the optimal individual dose of levodopa tends 
to remain fairly constant in any given patient over years.
52 Ob-
viously, more frequent doses may eventually be required to co-
unter levodopa wearing-off effects, but not progressively high-
er individual doses. 
There is a levodopa dosing range (discussed below) that cap-
tures the best possible response in all PD patients. There is a cei-
ling dose, beyond which, there is no further benefit. With this kn-
owledge, clinicians can escalate the dose to capture the most be-
nefit for any given patient.
Should levodopa be delayed?
Levodopa therapy works best during the first decade of PD. 
Some authors argue that you can “save” these best responses 
for later by deferring treatment. However, the likely reason that 
the earlier levodopa responses are more gratifying relates to the 
natural progression of PD. Thus, the Lewy neurodegenerative 
process is relentless, not only causing further nigral neuron loss, 
but also extending into widespread non-dopaminergic brain re-
gions.
43,44 Trying to “save” the best responses may simply trans-
late into missed opportunities and needless early disability. Mo-
reover, patients initially rendered house-confined due to under-
treatment may be difficult to subsequently return to an active 
lifestyle. 
Start a dopamine agonist first?
Despite the unequivocal superiority of levodopa, initial dopa-
mine agonist treatment is often advocated.
54,55 This primarily re-
lates to concerns for later-developing unstable levodopa respons-
es, with dyskinesias and motor fluctuations. Note however, that 
this is an age-related phenomenon. These are indeed a consid-
erable problem in the very young; among patients with PD on-Initial Treatment for Parkinson’s Disease
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set before age 40, both the dyskinesia-risk, and fluctuation-risk 
is over 95% after five years on levodopa.
56,57 However, more 
than 80% of PD patients present after age 60,
1 and in this age 
group, dyskinesia and fluctuation risks are markedly less. For 
those between ages 60-70, the dyskinesia risk after 5 years of 
levodopa is 26%; it drops to 16% after age 70.
58
It should also be noted that the published data on dyskinesia 
and fluctuation risks are incident data; these are frequencies re-
gardless of severity, persistence, or whether they were easily tr-
eated. In fact, these problems are quite treatable,
52 and some-
times are mild and do not require treatment. Thus, in one com-
munity-based study, the risk of dyskinesias that could not be 
adequately controlled with medication adjustments was only 
12% after ten years of levodopa therapy.
59
Several multi-center, controlled drug trials comparing initial 
dopamine agonist to levodopa therapy have shown less dyski-
nesias and fluctuations with the agonists.
27,60-64 However, an 
overlooked, consistent finding in all of these trials was signifi-
cantly less agonist efficacy in treating PD symptoms, despite 
allowing ad libitum levodopa added to agonist therapy. What 
also was clear from these studies was that monotherapy with an 
agonist was typically insufficient after 2-4 years, requiring add-
ed levodopa. 
Note that when dopamine agonists were first introduced many 
years ago, the strategy at that time was to add the agonist after 
levodopa fluctuations became problematic, with concurrent re-
duction of levodopa.
65-67 Overlooked is that the outcomes in th-
ese older trials appear very similar to those in the recent trials 
cited above, where the agonist was started first, before levodo-
pa. If fluctuations can be reduced by either starting the agonist 
first or deferring until they actually occur, why not wait? The ago-
nists are expensive and have unique side effects (see below); 
hence, it seems wise to defer them until they seem appropriate, 
later in the course.
Why not start with a dopamine agonist 
in this age group over 60 years?
Conservative use of the dopamine agonists seems wise, based 
on their potential for adverse events. The agonists now in com-
mon use around the world are pramipexole and ropinirole. In 
clinical trials, these each were approximately three times more 
likely than levodopa to cause hallucinations.
27,61-63 These two 
drugs also may induce somnolence or sleep attacks, which can 
be especially problematic among PD patients still driving.
68 In 
these clinical trials somnolence was documented in 27% to 38% 
of agonist-treated patients,
27,61-63 although other factors likely 
contributed. Also surfacing in clinical trials was leg edema, which 
occasionally can be massive and difficult to treat without stop-
ping the drug. 
Overlooked in the above published trials, was the remark-
able potential for pramipexole and ropinirole’ to provoke path-




70-72 and excessive and compulsive shopping/
spending money.
70,71,73,74 Among PD patients treated with ther-
apeutic doses of ropinirole or pramipexole in one community, 
the frequency of pathological gambling or hypersexuality was 
13%.
75 These side effects, in the aggregate, suggest that they 
should be deferred until clearly needed by PD patients over age 
60 years.
Should levodopa be started with a COMT 
inhibitor?
Some advocate starting levodopa combined with the Cate-
chol-O-methyl transferase (COMT) inhibitor, entacapone, ar-
guing that this longer-duration effect may provide less pulsa-
tile and more physiologic stimulation of dopamine receptors.
76,77 
The presumption is that this prolonged levodopa response will 
ultimately translate into a lower subsequent risk of dyskinesias 
and fluctuations. Note, however, that entacapone prolongs the le-
vodopa response by no more than 60 minutes.
78 This is actually 
a little less than the prolongation when levodopa is formulated 
as a controlled-release drug. When sustained-release levodopa 
was compared to immediate-release levodopa in 5 years clinical 
trials, dyskinesia and motor fluctuation frequencies were similar.
79,80 
Hence, there is no reason to expect that early use of entacapone 
would generate a different result.
Conclusion
Levodopa therapy is the most appropriate choice for initial 
treatment of PD patients over age 60 years. The dose should be 
adjusted to provide the best symptomatic benefit, allowing pa-
tients to remain active and engaged. 
Initiating Levodopa Therapy
Which formulation: sustained-release versus
regular (immediate-release)?
When the sustained-release formulations of levodopa were first 
introduced, they were advocated for initial therapy, arguing that 
the longer levodopa duration was more physiologic; presum-
ably, this would result in a lower subsequent risk of fluctua-
tions and dyskinesias. As cited above, this was investigated in 
two large, multi-center trials, with negative results;
79,80 after five 
years, patients randomized to sustained-release levodopa had 
essentially the same frequencies of motor fluctuations and dys-
kinesias as did those taking immediate-release levodopa. Since 
the prolongation of the response is modest (60-90 minutes),
81,82 
this is not surprising. 
There are some disadvantages to the sustained-release for-
mulation of levodopa. First, it is only about 70% bioavailable.
82 Ahlskog JE
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Although this can be compensated by using higher doses, there 
is concern when patients experience suboptimal responses that 
this may be due to poor absorption. 
Second, the sustained-release formulations have complex in-
teractions with meals. They are impeded from entering the cir-
culation when the stomach is empty.
82 However, circulating le-
vodopa is notoriously prevented from crossing the blood-brain 
barrier when taken with or after meals (via competition for trans-
port by protein-derived amino acids).
83 With immediate-release 
levodopa, meal influences can be eliminated by simply having 
patients take their doses an hour or more before meals, or two 
or more hours after meals.
52 How best to dose the sustained-re-
lease formulation to produce the most consistent clinical response 
has never been studied. Finally, in circumstances where patients 
must pay for their drugs, the added expense of sustained-relea-
se compounds influences prescribing habits.
Inhibition of dopa decarboxylase: 
carbidopa, benserazide
When levodopa was first introduced in the late 1960’s, large 
doses were necessary to overcome the rapid degradation by do-
pa decarboxylase (aromatic L-amino acid decarboxylase). More-
over, dopamine generated in the circulation by peripheral dopa 
decarboxylase, crossed into the brainstem chemoreceptive trig-
ger zone, provoking nausea and vomiting. The addition of the 
dopa decarboxylase inhibitors in the early 1970’s was a huge 
advance in the treatment of PD and they have become the stan-
dard of treatment. The two available decarboxylase inhibitors, 
carbidopa and benserazide are largely interchangeable with no 
apparent advantages of one over the other. A conventional dos-
age of each is 25 mg, formulated with 100 mg of levodopa. 
Carbidopa/levodopa and benserazide/levodopa
are similar
Dosing guidelines for the remainder of this manuscript will fo-
cus just on carbidopa/levodopa. This is to avoid redundancy sin-
ce benserazide/levodopa is dosed identically.
Initiating carbidopa/levodopa
Immediate-release carbidopa/levodopa is usually started using 
the 25/100 formulation. To avoid inhibition by dietary protein 
(amino acids), it is best taken an hour or more before meals. By 
convention, it is started three times daily. Although some clini-
cians favor starting with just a half of the 25/100 tablets three 
times daily, most patients tolerate a full tablet 3-times per day 
as the starting dose. Patients may be informed that this starting 
dose is often too low to provide noticeable benefit; otherwise, 
they may abandon the drug if not initially helpful. 
There is a long-duration effect from levodopa that requires 
about a week to fully manifest.
52,84 Hence, doses should be main-
tained for a week (or longer if desired) before escalating. The 
full benefit from carbidopa/levodopa taken on an empty stom-
ach is achieved by 2 ½ to 3 tablets of the 25/100 immediate-re-
lease formulation, each dose.
52 Doses higher than 3 tablets at a 
time provide no incremental benefit. Restated, the therapeutic 
range for carbidopa/levodopa is between 1-3 tablets each dose. 
With these premises in mind, a reasonable dose escalation sche-
dule is shown in the Table 1. Ultimately, the patient should maintain 
the most beneficial dose; however, if several doses are equally 
beneficial, they should then settle on the lowest of those equipo-
tent doses. As discussed above, there is no compelling evidence 
to suggest that arbitrarily low doses are preferable; patients sh-
ould be dosed with whatever works best for them. 
Levodopa Side Effects
Nausea
Despite carbidopa or benserazide, nausea occasionally occurs. 
This is transient among most patients. Taking the pills with dry 
bread, crackers of some other non-protein food may prove help-
ful. Centrally-acting dopamine blocking drugs, such as metoclo-
pramide or prochlorperazine, must be avoided. Domperidone 
blocks dopamine receptors but does not cross the blood-brain ba-
rrier; it is tolerated and a very effective anti-emetic. 
Plain carbidopa in 25 mg tablets is available to boost dopa 
decarboxylase inhibition, which may attenuate nausea; one to 
two of these tablets may be administered with or just before each 
carbidopa/levodopa dose. Carbidopa by itself appears to have no 
side effects or detrimental properties, so overdosage is not a con-
cern in this setting. 
Orthostatic hypotension
PD patients often have dysautonomia as a component of their 
condition. As a consequence, they may be prone to orthostatic 
hypotension. Hence, it is wise to measure the standing blood 
pressure (BP) before starting levodopa. Levodopa tends to low-
er the standing BP in susceptible patients for a few hours after 
each dose. Systolic BP’s below 100 mmHg before starting le-
vodopa raise concerns. Sometimes other drugs can be reduced 
or eliminated in that setting (e.g., diuretics, anti-hypertensives, 
Table 1. Initiation of therapy carbidopa/levodopa 25/100 immedi-
ate-release tablets
Week Tablets, each dose (taken 3 times daily*)
1 One
2 One & a half
3 Two
4 Two & a half
Option, week 5 Three 
*Conventionally administered at least one hour before each meal; 
if a meal is skipped, it may be taken at any time.Initial Treatment for Parkinson’s Disease
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alpha-1 adrenergic blockers for prostatism). Once levodopa is 
started, symptoms (presyncope) should not occur if the systolic 
BP remains consistently above 90 mmHg.
Hallucinations, delusions
Occasional PD patients experience hallucinations from levodo-
pa, but this is extremely rare if dementia is not present and if 
carbidopa/levodopa (or benserazide/levodopa) is the only psy-
choactive drug. If the initial doses of carbidopa/levodopa pro-
voke hallucinations, it is wise to scrutinize the medication list 
and eliminate other PD drugs or psychoactive medications.
Non-Motor Symptoms to Consider 
When Starting Levodopa
Titration of the levodopa dose to achieve optimum responses 
should target non-motor as well as the usual PD motor symp-
toms. Insomnia, anxiety, cramps are common and consistently 
levodopa responsive. Sometimes pain, paresthesia or depression 
also improves with levodopa.
52 Among occasional patients, dys-
pnea is a levodopa-responsive symptom,
52 although cardiopul-
monary causes should first be considered.
Insomnia
Insomnia beginning after PD onset is usually responsive to le-
vodopa.
52 Among new PD patients, the long-duration effect
84 
from daytime levodopa doses may carry-over through the night 
to allow sleep. If not, an additional dose of levodopa may be 
added an hour or so before bedtime. Patients adding a bedtime 
dose to counter insomnia should be advised to use the same full 
dose that they have identified as optimal for their waking-day 
symptoms; this tends to be an all-or-none response and lower 
doses may prove ineffective.
52
Insomnia is easily explained by known PD symptoms: aka-
thisia (inner restlessness), stiffness (rigidity), difficulty turning 
in bed, as well as tremor. These are all levodopa-responsive. 
Anxiety
Anxiety is a common non-motor symptom of PD and may even 
predate it by 20 years or more.
85 Occasionally, this is the most 
prominent complaint. It is responsive to levodopa in most cas-
es.
52 Patients also describe variations of this symptom that like-
wise are levodopa-responsive, including restlessness (akathisia), 
inability to get comfortable, inner tension or inner tremor.
Cramps
Cramps are common in all adults, but among PD patients, com-
plaints of “cramps” usually represent dystonia. Most common 
are toe “cramps”, with tonic deviation of the toes up or down. 
Dystonic foot inversion or calf cramps are also frequent com-
plaints, especially at night. Adequate levodopa coverage works 
better for these problems in PD than the usual medications for 
routine cramp syndromes such as quinine. As with insomnia, if 
the three daytime doses fail to control nocturnal “cramps”, a 
fourth full dose at bedtime may be added.
Conclusions
In this modern era with many new drugs for PD, levodopa ther-
apy often is relegated to an afterthought in discussions about 
treatment. It remains the most efficacious drug for dopamine de-
ficiency symptoms, by far. With proper dose adjustments it may 
maintain PD patients in the mainstreams of their lives for many 
years.
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